Y-mAbs Therapeutics (NASDAQ:YMAB) versus Its Peers Head-To-Head Review

Y-mAbs Therapeutics (NASDAQ: YMAB) is one of 548 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Y-mAbs Therapeutics to related businesses based on the strength of its earnings, dividends, institutional ownership, valuation, risk, profitability and analyst recommendations.

Institutional & Insider Ownership

25.4% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Y-mAbs Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Y-mAbs Therapeutics 0 0 5 0 3.00
Y-mAbs Therapeutics Competitors 4546 13020 27669 994 2.54

Y-mAbs Therapeutics currently has a consensus target price of $31.75, indicating a potential upside of 22.02%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.66%. Given Y-mAbs Therapeutics’ peers higher probable upside, analysts clearly believe Y-mAbs Therapeutics has less favorable growth aspects than its peers.

Profitability

This table compares Y-mAbs Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Y-mAbs Therapeutics N/A N/A N/A
Y-mAbs Therapeutics Competitors -1,760.46% -120.17% -28.09%

Earnings & Valuation

This table compares Y-mAbs Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Y-mAbs Therapeutics N/A -$43.27 million -17.35
Y-mAbs Therapeutics Competitors $2.15 billion $228.73 million -3.52

Y-mAbs Therapeutics’ peers have higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Y-mAbs Therapeutics peers beat Y-mAbs Therapeutics on 7 of the 12 factors compared.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.